Bora Pharmaceuticals (保瑞) announced its Q3 financial results on the 13th. Amidst generic drug price competition, internal supply transfer delays, and foreign exchange losses, the company recorded a net profit of NT$2.649 billion for the first three quarters, down 24.4% year-on-year, with earnings per share (EPS) of NT$21.34. For Q3 alone, net profit totaled NT$633 million, a 62.8% decline from the same period last year, with a quarterly EPS of NT$5.09.
Read more
